Publication:
Synthesis, biological evaluation and in silico study of bis-thiourea derivatives as anticancer, antimalarial and antimicrobial agents

dc.contributor.authorPingaew R.
dc.contributor.authorSinthupoom N.
dc.contributor.authorMandi P.
dc.contributor.authorPrachayasittikul V.
dc.contributor.authorCherdtrakulkiat R.
dc.contributor.authorPrachayasittikul S.
dc.contributor.authorRuchirawat S.
dc.contributor.authorPrachayasittikul V.
dc.date.accessioned2021-04-05T03:21:57Z
dc.date.available2021-04-05T03:21:57Z
dc.date.issued2017
dc.date.issuedBE2560
dc.description.abstractTwo sets of bis-thioureas including a para series (8–14) and a meta series (4, 5, 15–19), were synthesized and evaluated for their anticancer, antimalarial and antimicrobial activities. Most of the synthesized bis-thioureas, except for analogs 8–11, displayed cytotoxicity against MOLT-3 cell line (IC50 = 1.55–32.32 µM). Derivatives 5, 14, 18 and 19 showed a broad spectrum of anticancer activity. Analogs (4, 5, 8, 13, 14, 18 and 19) exhibited higher inhibitory efficacy in HepG2 cells than the control drug, etoposide. Significantly, bis-trifluoromethyl analog 19 was the promising potent cytotoxic agent (IC50 = 1.50–18.82 µM) with the best safety index (1.64–20.60). Antimalarial activity results showed that trifluoromethyl derivative 18 was the most potent compound (IC50 = 1.92 µM, selective index = 6.86). Antimicrobial activity revealed that bis-thioureas 12, 18 and 19 exhibited selective activity against Gram-positive bacteria and fungi. Promisingly, the bis-trifluoromethyl derivative 19 was the most potent compound in the series and displayed higher potency, against most of the Gram-positive bacteria and fungi, than that of ampicillin, the reference drug. Among the tested strains of microorganisms, compound 19 inhibited the growth of Staphylococcus epidermidis ATCC 12228 and Micrococcus luteus ATCC 10240 with the lowest MIC of 1.47 µM. The findings demonstrated that trifluoromethyl group plays a crucial role in their biological activities. Furthermore, the molecular docking was performed to reveal possible binding modes of the compounds against target proteins. © 2017, Springer Science+Business Media, LLC.
dc.format.mimetypeapplication/pdf
dc.identifier.citationMedicinal Chemistry Research. Vol 26, No.12 (2017), p.3136-3148
dc.identifier.doi10.1007/s00044-017-2008-5
dc.identifier.issn10542523
dc.identifier.other2-s2.0-85028960760
dc.identifier.urihttps://hdl.handle.net/20.500.14740/3993
dc.rights.holderScopus
dc.subject.other1,1' [1,3 phenylenebis(methylene)]bis[3 (4 bromophenyl)thiourea]
dc.subject.other1,1' [1,3 phenylenebis(methylene)]bis[3 (4 methoxyphenyl)thiourea]
dc.subject.other1,1' [1,3 phenylenebis(methylene)]bis[3 (4 trifluoromethylphenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (3,5 ditrifluoromethylphenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (4 bromophenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (4 chlorophenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (4 methoxyphenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (4 methylphenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (4 nitrophenyl)thiourea]
dc.subject.other1,1' [1,4 phenylenebis(methylene)]bis[3 (4 trifluoromethylphenyl)thiourea]
dc.subject.otherAmpicillin
dc.subject.otherAntiinfective agent
dc.subject.otherAntimalarial agent
dc.subject.otherAntineoplastic agent
dc.subject.otherColchicine
dc.subject.otherCytotoxic agent
dc.subject.otherDNA topoisomerase IV
dc.subject.otherDoxorubicin
dc.subject.otherEtoposide
dc.subject.otherNovobiocin
dc.subject.otherThiourea derivative
dc.subject.otherTubulin
dc.subject.otherUnclassified drug
dc.subject.otherAchromobacter xylosoxidans
dc.subject.otherAgar dilution
dc.subject.otherAnimal cell
dc.subject.otherAntimalarial activity
dc.subject.otherAntimicrobial activity
dc.subject.otherAntineoplastic activity
dc.subject.otherArticle
dc.subject.otherBacillus cereus
dc.subject.otherBacillus subtilis
dc.subject.otherBinding site
dc.subject.otherCarbon nuclear magnetic resonance
dc.subject.otherComputer model
dc.subject.otherControlled study
dc.subject.otherCytotoxicity
dc.subject.otherDrug potency
dc.subject.otherDrug safety
dc.subject.otherDrug screening
dc.subject.otherDrug structure
dc.subject.otherDrug synthesis
dc.subject.otherHep-G2 cell line
dc.subject.otherHuman
dc.subject.otherHuman cell
dc.subject.otherHydrogen bond
dc.subject.otherIC50
dc.subject.otherInfrared spectroscopy
dc.subject.otherListeria monocytogenes
dc.subject.otherMass spectrometry
dc.subject.otherMicrococcus luteus
dc.subject.otherMinimum inhibitory concentration
dc.subject.otherMolecular docking
dc.subject.otherMOLT-3 cell line
dc.subject.otherNonhuman
dc.subject.otherPlasmodium falciparum
dc.subject.otherPlesiomonas shigelloides
dc.subject.otherProton nuclear magnetic resonance
dc.subject.otherSaccharomyces cerevisiae
dc.subject.otherSelectivity index
dc.subject.otherShigella dysenteriae
dc.subject.otherStaphylococcus epidermidis
dc.titleSynthesis, biological evaluation and in silico study of bis-thiourea derivatives as anticancer, antimalarial and antimicrobial agents
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85028960760&doi=10.1007%2fs00044-017-2008-5&partnerID=40&md5=91ceae2e75b0123b27cff398f7db21b7

Files